The PBAC has recommended a listing for the drospirenone-only contraceptive pill, acknowledging it is important for women to have a range of affordable options.

At its November meeting, the committee recommended an unrestricted listing for once-daily drospirenone 4mg (Slinda), which has been available on private script for $80 a month since 2021.

The PBAC said this pill had benefits over other listed options, including having a longer pill-free window compared with other progestogen-only pills, and would provide an additional option for patients who could not use oestrogen-containing contraceptives.

“The PBAC noted comments from clinicians … and other health professionals and individuals, highlighting the importance of having a range of contraceptive options available on the PBS so that cost is not a barrier to accessing the most appropriate contraceptive,” the committee reported in its outcomes statement.